Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
If you love creative paracord projects, mind-blowing weaves, and unique survival gear, you need to follow me! Join the Weavers of Eternity community for expert tutorials, fun challenges, and must-know ...
On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
Following a ~39% drop in the previous session, Replimune (NASDAQ:REPL) shares continued to trade lower on Friday as J.P. Morgan downgraded the stock to Underweight from Neutral, citing further ...
The appetite for digital content smashed all records during last year’s summer Olympics in Paris. And it wasn’t solely the sporting events that attracted more eyeballs than ever before across ...
The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...
As of September 11, 2025, Replimune Group, Inc. had a $469.1 million market capitalization, putting it in the 39th percentile of companies in the Biotechnology industry. Replimune Group, Inc. does not ...
Hosted on MSN
JavaScript: How It Actually Works
Ever wondered how JavaScript really works? In this video, we break down the computer science behind the world’s most popular programming language - from source code to execution? Learn how the engine ...
Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback